J. Oddens Et Al. , "Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance," EUROPEAN UROLOGY , vol.63, no.3, pp.462-472, 2013
Oddens, J. Et Al. 2013. Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. EUROPEAN UROLOGY , vol.63, no.3 , 462-472.
Oddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., ... Gontero, P.(2013). Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. EUROPEAN UROLOGY , vol.63, no.3, 462-472.
Oddens, Jorg Et Al. "Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance," EUROPEAN UROLOGY , vol.63, no.3, 462-472, 2013
Oddens, Jorg Et Al. "Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance." EUROPEAN UROLOGY , vol.63, no.3, pp.462-472, 2013
Oddens, J. Et Al. (2013) . "Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance." EUROPEAN UROLOGY , vol.63, no.3, pp.462-472.
@article{article, author={Jorg Oddens Et Al. }, title={Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance}, journal={EUROPEAN UROLOGY}, year=2013, pages={462-472} }